Penile erectile responses to electric stimulation are enhanced by a new phosphodiesterase type-5 inhibitor.
OBJECTIVE
This study was conducted to investigate the effect of DA-8159, a new phosphodiesterase type-5 (PDE5) inhibitor, on electrostimulation-induced penile erection in rats.


METHODS
Intracavernous pressure (ICP) and arterial blood pressure (BP) were simultaneously recorded through electric pelvic-ganglion stimulation (2-10 Hz) after the oral administration of DA-8159 (3 or 10 mg/kg) in normal and streptozotocin-induced diabetic rats. Statistical analysis was performed on the maximal intracavernous pressure (ICP), detumescence time, maximal intracavernous pressure/blood pressure (ICP/BP) ratio, and the area under the curve (AUC) of the ICP/BP ratio.


RESULTS
In normal and diabetic rats, electrical stimulation of the pelvic ganglion induced a frequency- and dose-dependent increase in the intracavernous pressure. The ICP/BP ratio and the corresponding AUC values were also significantly and dose-dependently increased after DA-8159 administration. In addition, the detumescence time significantly increased after DA-8159 administration compared to that of the controls.


CONCLUSIONS
These results show that the DA-8159 significantly increased the intracavernous pressure response and prolonged the decay period induced by electrical stimulation of the pelvic ganglion, and suggest that DA-8159 might be a potential therapeutic agent for the treatment of erectile dysfunction.
Yu
Jae Young
JY
Research Institutes of Dong-A Pharmaceutical Company, Kyunggi, Korea.
Kang
Kyung Koo
KK
Yoo
Moohi
M
Kwon
Jong Won
JW
D000818:Animals; D003921:Diabetes Mellitus, Experimental; D004558:Electric Stimulation / Q000379:methods*; D007001:Hypogastric Plexus / Q000187:drug effects / Q000502:physiology; D008297:Male; D008365:Manometry; D010410:Penile Erection / Q000187:drug effects* / Q000502:physiology; D010413:Penis / Q000503:physiopathology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011312:Pressure; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides; D000096926:Benzenesulfonamides
D010726:Phosphodiesterase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; C419664:udenafil; D000096926:Benzenesulfonamides